Literature DB >> 24882752

Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms.

Giovanni Meola1, Rosanna Cardani2.   

Abstract

Myotonic dystrophy (DM) is the most common adult muscular dystrophy, characterized by autosomal dominant progressive myopathy, myotonia and multiorgan involvement. To date two distinct forms caused by similar mutations have been identified. Myotonic dystrophy type 1 (DM1, Steinert's disease) is caused by a (CTG)n expansion in DMPK, while myotonic dystrophy type 2 (DM2) is caused by a (CCTG)n expansion in ZNF9/CNBP. When transcribed into CUG/CCUG-containing RNA, mutant transcripts aggregate as nuclear foci that sequester RNA-binding proteins, resulting in spliceopathy of downstream effector genes. However, it is now clear that additional pathogenic mechanism like changes in gene expression, protein translation and micro-RNA metabolism may also contribute to disease pathology. Despite clinical and genetic similarities, DM1 and DM2 are distinct disorders requiring different diagnostic and management strategies. This review is an update on the recent advances in the understanding of the molecular mechanisms behind myotonic dystrophies. This article is part of a Special Issue entitled: Neuromuscular Diseases: Pathology and Molecular Pathogenesis.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical finding; Molecular mechanism; Muscle biopsy; Myotonic dystrophy type 1; Myotonic dystrophy type 2; Pathology

Mesh:

Substances:

Year:  2014        PMID: 24882752     DOI: 10.1016/j.bbadis.2014.05.019

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  114 in total

Review 1.  Repeat-associated RNA structure and aberrant splicing.

Authors:  Melissa A Hale; Nicholas E Johnson; J Andrew Berglund
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-16       Impact factor: 4.490

2.  Electromechanical delays during a fatiguing exercise and recovery in patients with myotonic dystrophy type 1.

Authors:  Fabio Esposito; Emiliano Cè; Susanna Rampichini; Elena Monti; Eloisa Limonta; Barbara Fossati; Giovanni Meola
Journal:  Eur J Appl Physiol       Date:  2017-02-14       Impact factor: 3.078

3.  Brain MRI abnormalities in the adult form of myotonic dystrophy type 1: A longitudinal case series study.

Authors:  Renata Conforti; Mario de Cristofaro; Adriana Cristofano; Barbara Brogna; Angela Sardaro; Gioacchino Tedeschi; Sossio Cirillo; Alfonso Di Costanzo
Journal:  Neuroradiol J       Date:  2016-01-11

Review 4.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

5.  Distinct pathological signatures in human cellular models of myotonic dystrophy subtypes.

Authors:  Ellis Y Kim; David Y Barefield; Andy H Vo; Anthony M Gacita; Emma J Schuster; Eugene J Wyatt; Janel L Davis; Biqin Dong; Cheng Sun; Patrick Page; Lisa Dellefave-Castillo; Alexis Demonbreun; Hao F Zhang; Elizabeth M McNally
Journal:  JCI Insight       Date:  2019-03-21

Review 6.  How Research on Human Progeroid and Antigeroid Syndromes Can Contribute to the Longevity Dividend Initiative.

Authors:  Fuki M Hisama; Junko Oshima; George M Martin
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

Review 7.  Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis.

Authors:  Sami J Barmada
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 8.  On the wrong DNA track: Molecular mechanisms of repeat-mediated genome instability.

Authors:  Alexandra N Khristich; Sergei M Mirkin
Journal:  J Biol Chem       Date:  2020-02-14       Impact factor: 5.157

9.  Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink.

Authors:  Youjin Wang; Ruth M Pfeiffer; Rotana Alsaggaf; Wilhelmine Meeraus; Julia C Gage; Lesley A Anderson; Renée C Bremer; Nikoletta Nikolenko; Hanns Lochmuller; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2017-11-20       Impact factor: 7.396

Review 10.  Myotonic Dystrophy Type 1 Management and Therapeutics.

Authors:  Cheryl A Smith; Laurie Gutmann
Journal:  Curr Treat Options Neurol       Date:  2016-12       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.